drugset / Trial / NCT03604289

Angiotensin 1-7 in Obesity Hypertension

NCT03604289

Phase 0 Terminated 8 enrolled Amy Arnold American Heart Association · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.

Timeline

Start
2019-04-01
Primary completion
2023-05-03
Completion
2023-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject talfirastide Peptide 8 unknown Intravenous